ROCHE-WO20697



A randomized, open label study to compare the complete pathological response rate achieved with 4 combinations of Herceptin, docetaxel and pertuzumab in patients with locally advanced, inflammatory or early stage HER2 positive breast cancer
Pertuzumab
WO20697
NCT00545688
malignant neoplasm of breast
Phase 2
 
October 2016